This Week in HIV Research: How Antiretrovirals May Affect Birth

This Week in HIV Research: How Antiretrovirals May Affect Birth

1 of 5
Next >

With each edition of our Week in HIV Research series, we aim to briefly shine a spotlight on studies with potential clinical importance that may nonetheless fall by the wayside amidst the constant stream of published and presented research on HIV. This week is no different, as we turn our eye toward noteworthy recent findings focusing in particular on women and people who inject drugs. On the docket this time:

  • One of the most detailed explorations yet around the effect of HIV treatment on preterm delivery or low-birthweight babies.
  • A microcosm of the obstacles faced by providers seeking to increase pre-exposure prophylaxis (PrEP) usage among U.S. women.
  • A highly successful, and relatively simple, set of interventions changing the lives of HIV-positive people who inject drugs.
  • Supplemental data adding to our understanding of chronic kidney disease among people taking "old" tenofovir.

Let's take a closer look at each of these findings, shall we? To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody.com and TheBodyPRO.com. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: monkeybusinessimages for iStock via Thinkstock

With each edition of our Week in HIV Research series, we aim to briefly shine a spotlight on studies with potential clinical importance that may nonetheless fall by the wayside amidst the constant stream of published and presented research on HIV. This week is no different, as we turn our eye toward noteworthy recent findings focusing in particular on women and people who inject drugs. On the docket this time:

  • One of the most detailed explorations yet around the effect of HIV treatment on preterm delivery or low-birthweight babies.
  • A microcosm of the obstacles faced by providers seeking to increase pre-exposure prophylaxis (PrEP) usage among U.S. women.
  • A highly successful, and relatively simple, set of interventions changing the lives of HIV-positive people who inject drugs.
  • Supplemental data adding to our understanding of chronic kidney disease among people taking "old" tenofovir.

Let's take a closer look at each of these findings, shall we? To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody.com and TheBodyPRO.com. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: monkeybusinessimages for iStock via Thinkstock